Observational study: daily treatment with a new compound "Tradamixina" plus serenoa repens for two months improved the lower urinary tract symptoms
- PMID: 23173650
- PMCID: PMC3499205
- DOI: 10.1186/1471-2482-12-S1-S22
Observational study: daily treatment with a new compound "Tradamixina" plus serenoa repens for two months improved the lower urinary tract symptoms
Retraction in
-
Retraction Note: Observational study: daily treatment with a new compound "tradamixina" plus serenoa repens for two months improved the lower urinary tract symptoms.BMC Surg. 2016 Apr 28;16(1):23. doi: 10.1186/s12893-016-0139-0. BMC Surg. 2016. PMID: 27121967 Free PMC article. No abstract available.
Abstract
Background: Lower urinary tract symptoms (LUTS) are associated with great emotional costs to individuals and substantial economic costs to society. This study seeks to evaluate the effect of a new natural compound "Tradamixina plus Serenoa Repens" in order to improve lower urinary tract symptoms.
Methods: 100 patients (≥ 45 years) who had had LUTS/BPH for >6 mo at screening and with IPSS -The international Prostate symptom scores- ≥ 13 and maximum urinary flow rate (Qmax) ≥ 4 to ≤ 15 ml/s. were recruited. The compound "Tradamixina plus Serenoa Repens" (80 mg of Alga Ecklonia Bicyclis, 100 mg of Tribulus Terrestris and 100 mg of D-Glucosamine and N-Acetyl-D-Glucosamine plus 320 mg of Serenoa Repens) was administered daily for 2 months. At visit and after 60 days of treatment patients were evaluated by means of detailed medical urological history, clinical examination, laboratory investigations (total PSA), and instrumental examination like urolfowmetry. Efficacy measures included IPSS-International Prostate Sympto, BPH Impact Index (BII), Quality-of-Life (QoL) Index. Measures were assessed at baseline and end point (12 wk or end of therapy) and also at screening, 1 and 4 wk for IPSS, and 4 wk for BII. Statistical significance was interpreted only if the results of the preceding analysis were significant at the 0.05 level.
Results: After 2 months of treatment the change from baseline to week 12 relative to "Tradamixina plus Seronea Repens" in total IPSS and Qol was statistically significant. Differences from baseline in BII were statistically significant for "Tradamixina plus Seronea Repens" above all differences in BII were also significant at 4 wk (LSmean ± SE: -0.8 ± 0.2). In the distribution of subjects over the PGI-I and CGI-I response categories were significant for"Tradamixina plus Seronea Repens" (PGI-I: p = 0.001; CGI-I). We also observed a decrease of total PSA.
Conclusion: The daily treatment with a new compound "Tradamixina plus Serenoa Repens" for 2 months improved the male sexual function , it improved the bother symptoms which affect the patient's quality of life , improved uroflowmetric parameters, and we also observed a decrease of serum PSA level.
Similar articles
-
Sexual asthenia: Tradamixina versus Tadalafil 5 mg daily.BMC Surg. 2012;12 Suppl 1(Suppl 1):S23. doi: 10.1186/1471-2482-12-S1-S23. Epub 2012 Nov 15. BMC Surg. 2012. PMID: 23173697 Free PMC article. Clinical Trial.
-
Observational database serenoa repens (DOSSER): overview, analysis and results. A multicentric SIUrO (Italian Society of Oncological Urology) project.Arch Ital Urol Androl. 2012 Sep;84(3):117-22. Arch Ital Urol Androl. 2012. PMID: 23210402
-
Comparison of tamsulosin plus serenoa repens with tamsulosin in the treatment of benign prostatic hyperplasia in Korean men: 1-year randomized open label study.Urol Int. 2015;94(2):187-93. doi: 10.1159/000366521. Epub 2015 Jan 23. Urol Int. 2015. PMID: 25614155 Clinical Trial.
-
Efficacy and safety of a hexanic extract of Serenoa repens (Permixon® ) for the treatment of lower urinary tract symptoms associated with benign prostatic hyperplasia (LUTS/BPH): systematic review and meta-analysis of randomised controlled trials and observational studies.BJU Int. 2018 Dec;122(6):1049-1065. doi: 10.1111/bju.14362. Epub 2018 Jun 6. BJU Int. 2018. PMID: 29694707
-
Comparison of Serenoa repens With Tamsulosin in the Treatment of Benign Prostatic Hyperplasia: A Systematic Review and Meta-Analysis.Am J Mens Health. 2020 Mar-Apr;14(2):1557988320905407. doi: 10.1177/1557988320905407. Am J Mens Health. 2020. PMID: 32274957 Free PMC article.
Cited by
-
Role of complimentary therapy for male LUTS.Curr Urol Rep. 2013 Dec;14(6):606-13. doi: 10.1007/s11934-013-0372-3. Curr Urol Rep. 2013. PMID: 24026362
-
Retraction Note: Observational study: daily treatment with a new compound "tradamixina" plus serenoa repens for two months improved the lower urinary tract symptoms.BMC Surg. 2016 Apr 28;16(1):23. doi: 10.1186/s12893-016-0139-0. BMC Surg. 2016. PMID: 27121967 Free PMC article. No abstract available.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous